Shnayder, N.A.,
Grechkina, V.V.,
Khasanova, A.K.,
Bochanova, E.N.,
Dontceva, E.A.,
Petrova, M.M.,
Asadullin, A.R.,
Shipulin, G.A.,
Altynbekov, K.S.,
Al-Zamil, M.,
Nasyrova, R.F. (2023) from the standpoint of the pharmacogenomics and pharmacometabolomics. In addition, a new
personalizedNasyrova, Regina F.,
Shnayder, Natalia A.,
Osipova, Sofia M.,
Khasanova, Aiperi K.,
Efremov, Ilya S.,
Al-Zamil, Mustafa,
Petrova, Marina M.,
Narodova, Ekaterina A.,
Garganeeva, Natalia P.,
Shipulin, German A. (2023) this risk can be partially modified by the
personalized
selection of APs and their dosing rates, taking